TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16765272

Group type: EXPERIMENTAL
Intervention: Single data extraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double data extraction
Number of subjects: 0
Study: 15581425

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg b.d. for 7 days or until discharge
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 11718218

Group type: EXPERIMENTAL
Intervention: Higher lesional viral load at study entry
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HPV-6
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HPV-11
Number of subjects: 40

Group type: COMPARATOR
Intervention: HPV-16
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HPV-61
Number of subjects: 40

Group type: COMPARATOR
Intervention: Demographic and epidemiological data, or risk factors
Number of subjects: 40
Study: 8511635

Group type: EXPERIMENTAL
Intervention: Experimental group with situational involvement (decision reviewed by peers)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group without situational involvement
Number of subjects: 48
Study: 3498392

Group type: EXPERIMENTAL
Intervention: 1 mg X kg‐1 propofol
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1.5 mg X kg‐1 ketamine
Number of subjects: 16
Study: 323835

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (Disadine D.P.)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control (no povidone-iodine)
Number of subjects: 101
Study: 29489726

Group type: EXPERIMENTAL
Intervention: Single-leg Roman chair hold
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nordic hamstring curl
Number of subjects: 12
Study: 28199996

Group type: EXPERIMENTAL
Intervention: First-trimester placental growth factor (PlGF) measurements at 8+0 to 10+6 weeks and 11+0 to 14+0 weeks of gestation.
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: First-trimester placental growth factor (PlGF) measurements.
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: Δ‐PlGF in pregnancies complicated by PE.
Number of subjects: 814
Study: 26302249

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive psychoeducation (CPE)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study: 22780582

Group type: EXPERIMENTAL
Intervention: 7.5% CO₂ inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medical air (placebo)
Number of subjects: 0
Study: 21195255

Group type: EXPERIMENTAL
Intervention: Damon Q
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In‐Ovation R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Speed
Number of subjects: 0
Study: 18617176

Group type: COMPARATOR
Intervention: Controls (7 patients)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with CAD (5 patients)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with AnCAD (5 patients)
Number of subjects: 17
Study: 17364151

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LG)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Anterior-open repair (OG)
Number of subjects: 170
Study: 15550798

Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 1299

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1299

Group type: COMPARATOR
Intervention: Quality Improvement (QI) programs
Number of subjects: 1299
Study: 11152830

Group type: EXPERIMENTAL
Intervention: NIR stent
Number of subjects: 849

Group type: COMPARATOR
Intervention: PS stent
Number of subjects: 849
Study: 9451886

Group type: EXPERIMENTAL
Intervention: Tc-99m-methyl-diphosphate (MDP) bone scans
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sestamibi (MIBI) bone scans
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MIBI bone scans post-chemotherapy
Number of subjects: 15
Study: 8179134

Group type: EXPERIMENTAL
Intervention: 0.1 mg human corticotropin releasing hormone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 0.2 mg human corticotropin releasing hormone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no human corticotropin releasing hormone)
Number of subjects: 42
Study: 3332509

Group type: EXPERIMENTAL
Intervention: 2 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3 tablets of 'Fansimef' (500 mg mefloquine base, 1000 mg sulfadoxine, 50 mg pyrimethamine)
Number of subjects: 60
Study: 29999517

Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition (IMPACT®)
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Postoperative immunonutrition (IMPACT®)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Perioperative standard nutrition
Number of subjects: 276

Group type: COMPARATOR
Intervention: Preoperative standard nutrition
Number of subjects: 276
Study: 28800722

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 121

Group type: COMPARATOR
Intervention: Propofol-remifentanil
Number of subjects: 121
Study: 26361810

Group type: EXPERIMENTAL
Intervention: Calcium phosphate containing desensitizer paste (TAP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Water as placebo (PLA)
Number of subjects: 35
Study: 24028716

Group type: EXPERIMENTAL
Intervention: CD4(+) T cells from IRH patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: CD4(+) T cells from aplastic anemia patients
Number of subjects: 40
Study: 21145578

Group type: EXPERIMENTAL
Intervention: 15 μg dose of 2009 H1N1 vaccine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 30 μg dose of 2009 H1N1 vaccine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 15 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 30 μg dose of 2009 H1N1 vaccine in patients older than 60 years with severe asthma
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Both 15 μg and 30 μg doses of 2009 H1N1 vaccine
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: 2009 H1N1 vaccine
Number of subjects: 390
Study: 18509570

Group type: EXPERIMENTAL
Intervention: Group-based support (n = 12)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Individual occupation-based support (n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combined group and individual support intervention (n = 12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 35
Study: 17115871

Group type: EXPERIMENTAL
Intervention: Ketamine 0.2 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketamine 0.4 mg/kg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 14985213

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (40 g soy protein, 118 mg isoflavones)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Casein placebo
Number of subjects: 50
Study: 11687731

Group type: EXPERIMENTAL
Intervention: ACE-inhibitor trandolapril (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-dihydropyridinic Ca2+ channel blocker verapamil (240 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of trandolapril (2 mg) and verapamil (180 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study: 9405587

Group type: EXPERIMENTAL
Intervention: 850 microg/d synthetic folic acid
Number of subjects: 24

Group type: COMPARATOR
Intervention: 450 microg/d synthetic folic acid
Number of subjects: 24
Study: 12959316

Group type: EXPERIMENTAL
Intervention: Racemic tranylcypromine (20 mg of the sulphate)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Single enantiomers of tranylcypromine (10 mg of the sulphate)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Both enantiomers
Number of subjects: 6
Study: 2872878

Group type: EXPERIMENTAL
Intervention: Ticarcillin
Number of subjects: 261

Group type: COMPARATOR
Intervention: Tinidazole
Number of subjects: 261
Study: 31957104

Group type: EXPERIMENTAL
Intervention: Stroke volume-based fluid resuscitation protocol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no protocol)
Number of subjects: 64
Study: 30462706

Group type: EXPERIMENTAL
Intervention: Binocular fixation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dominant eye fixation
Number of subjects: 35

Group type: COMPARATOR
Intervention: Non-dominant eye fixation
Number of subjects: 35
Study: 28712216

Group type: EXPERIMENTAL
Intervention: Clamping trial before removal (Group A)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Immediate removal without clamping trial (Group B)
Number of subjects: 180
Study: 24739993

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 165

Group type: COMPARATOR
Intervention: Matching placebo tablets
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Supervised dietary program (offered to randomized participants)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Blood specimens from controls without IIH
Number of subjects: 165
Study: 23418301

Group type: EXPERIMENTAL
Intervention: Action‐observation training (AOT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard Toy Observation Training (TOT)
Number of subjects: 52
Study: 20185897

Group type: EXPERIMENTAL
Intervention: Endurance training (n = 18)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Strength training (n = 15)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Autogenic training (control group, n = 5)
Number of subjects: 38
Study: 18079431

Group type: EXPERIMENTAL
Intervention: Perioperative parecoxib 40 mg
Number of subjects: 320

Group type: COMPARATOR
Intervention: Postoperative parecoxib
Number of subjects: 320

Group type: COMPARATOR
Intervention: Single preoperative parecoxib dose
Number of subjects: 320
Study: 16563131

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oxybutynin
Number of subjects: 60
Study: 12584282

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa at doses of 0.45 and 0.75 microg/kg/week
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa continued for up to 52 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 122
Study: 11041909

Group type: EXPERIMENTAL
Intervention: Rofecoxib (12.5, 25, or 50 mg combined)
Number of subjects: 5435

Group type: COMPARATOR
Intervention: NSAIDs (ibuprofen, diclofenac, or nabumetone combined)
Number of subjects: 5435
Study: 8640968

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 392

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 392
Study: 1377305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nitrendipine (morning dosage) 20 mg
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Nitrendipine (evening dosage) 20 mg
Number of subjects: 34
Study: 6730873

Group type: EXPERIMENTAL
Intervention: Pethidine 25 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sodium chloride 0.9% (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Morphine 2.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 micrograms
Number of subjects: 100
Study: 31183923

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen screening and digital rectal examination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29486797

Group type: EXPERIMENTAL
Intervention: BTH1677 (4 mg/kg IV weekly) + bevacizumab (15 mg/kg IV Q3W) + carboplatin (6 mg/mL/min Calvert formula Q3W) + paclitaxel (200 mg/m2 Q3W)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (bevacizumab + carboplatin + paclitaxel as above)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: BTH1677 arm
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: BTH1677/bevacizumab/carboplatin/paclitaxel
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 92
Study: 27622613

Group type: EXPERIMENTAL
Intervention: Standard pin configuration
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Dorgan's method
Number of subjects: 138
Study: 24699939

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg every 2 weeks (q2w)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Sirukumab 100 mg q2w
Number of subjects: 187

Group type: COMPARATOR
Intervention: Sirukumab (all doses)
Number of subjects: 187
Study: 21316934

Group type: EXPERIMENTAL
Intervention: Phytosterol supplementation (4 g per day via 2 plant sterol-enriched yogurt mini drinks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (yogurt beverage without phytosterols)
Number of subjects: 108
Study: 19769596

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO) for 12 days (Study 1)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo beverage (PRO) for 12 days (Study 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO) for 21 days (Study 2)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo beverage (PRO) for 21 days (Study 2)
Number of subjects: 50
Study: 17563146

Group type: EXPERIMENTAL
Intervention: BI‐A (2 sessions with the adolescent only)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: BI‐AP (2 sessions with the adolescent and 1 with the parent)
Number of subjects: 79

Group type: COMPARATOR
Intervention: CON (assessment‐only control condition)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 79
Study: 15591331

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sevoflurane/nitrous oxide (Group S)
Number of subjects: 42
Study: 12391385

Group type: EXPERIMENTAL
Intervention: 200 microg/day of folic acid
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 400 microg/day of folic acid
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 100 microg/day of folic acid
Number of subjects: 95

Group type: COMPARATOR
Intervention: 0 microg/day of folic acid (placebo)
Number of subjects: 95
Study: 9920100

Group type: EXPERIMENTAL
Intervention: GH replacement therapy
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7484282

Group type: EXPERIMENTAL
Intervention: Calcium tablets 1 g/night
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Milk powder containing 1 g of calcium
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Calcium tablets 1 g/night and exercise regimen
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 2301454

Group type: EXPERIMENTAL
Intervention: Low-dose combined drug therapy (propranolol and chlorthalidone) with an educational program on hypertension, dietary and exercise modification.
Number of subjects: 95

Group type: COMPARATOR
Intervention: High-comparison group (control) receiving no specific intervention.
Number of subjects: 95
Study: 7028089

Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Betamethasone phosphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 0
Study: 30761486

Group type: EXPERIMENTAL
Intervention: EDTA amendment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BC amendment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28655538

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Sham control (riboflavin alone without removal of the epithelium)
Number of subjects: 179
Study: 26826113

Group type: EXPERIMENTAL
Intervention: Physically active academic lessons (2 consecutive school years, 22 weeks per year, 3 times a week, 20-30 min per lesson)
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 499
Study: 24972949

Group type: EXPERIMENTAL
Intervention: Traditional trivalent split virion vaccine (TIIV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV)
Number of subjects: 60
Study: 22653877

Group type: EXPERIMENTAL
Intervention: L‐AMT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: D‐AMT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: L/D‐AMT
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: In vitro uptake by the human proton‐coupled folate transporter (PCFT)
Number of subjects: 61
Study: 19289172

Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 2.5 mg/kg caffeine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5 mg/kg caffeine
Number of subjects: 27

Group type: COMPARATOR
Intervention: saline
Number of subjects: 27
Study: 17227904

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide, thalidomide, and prednisone (CTP)
Number of subjects: 37
Study: 15954068

Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 18
Study: 11893836

Group type: EXPERIMENTAL
Intervention: TELE
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: TICS
Number of subjects: 56
Study: 9468751

Group type: EXPERIMENTAL
Intervention: Experimental group asked to reduce salivation
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Experimental group asked to reduce salivation and promised a reward if successful
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3
Study: 7657279

Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 18

Group type: COMPARATOR
Intervention: No albumin infusion (Control)
Number of subjects: 18
Study: 2663695

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon-2a, 9 million units intramuscularly three times weekly for 16 weeks, followed by 3 million units three times weekly for an additional 8 weeks if viremic after 16 weeks.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Untreated control group (12 patients).
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon-2a (treated group).
Number of subjects: 30
Study: 1151628

Group type: EXPERIMENTAL
Intervention: Elixir, 0.5 mg digoxin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rapid dissolution tablet, 0.5 mg digoxin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Slow dissolution tablet, 0.5 mg digoxin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Intravenous administration, 0.5 mg digoxin
Number of subjects: 16
Study: 29554013

Group type: EXPERIMENTAL
Intervention: HF-NMES (60 Hz)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: LF-NMES (20 Hz)
Number of subjects: 11
Study: 28774317

Group type: EXPERIMENTAL
Intervention: NP-led care
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard care (usual cardiologist consultation)
Number of subjects: 70
Study: 26437761

Group type: EXPERIMENTAL
Intervention: Oral sodium nitrate (NO donor)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 24521888

Group type: EXPERIMENTAL
Intervention: Furazolidone-based quadruple therapy (Esomeprazole 20 mg twice daily, furazolidone 100 mg twice daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Levofloxacin-based quadruple therapy (Esomeprazole 20 mg twice daily, levofloxacin 500 mg daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Number of subjects: 156
Study: 21248158

Group type: EXPERIMENTAL
Intervention: 2 doses of HPV vaccine (Gardasil) for group 1, months 0 and 6
Number of subjects: 824

Group type: EXPERIMENTAL
Intervention: 3 doses of HPV vaccine (Gardasil) for group 2, months 0, 2, and 6
Number of subjects: 824

Group type: COMPARATOR
Intervention: 3 doses of HPV vaccine (Gardasil) for group 3, months 0, 2, and 6
Number of subjects: 824
Study: 18081355

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 400 microg buccally
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT) 400 microg sublingually
Number of subjects: 90
Study: 16448525

Group type: EXPERIMENTAL
Intervention: Sibutramine 10 or 15 mg continuously for 12 months
Number of subjects: 928
Study: 14567773

Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg daily
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 11375775

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone (PTH) delivered intermittently at low doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New PTH analogues
Number of subjects: 0
Study: 9758073

Group type: EXPERIMENTAL
Intervention: Integrated psychological treatment program (self-help techniques, cognitive behavioral strategies, relaxation, physical exercises)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (autogenic training)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Integrated psychological treatment program
Number of subjects: 27
Study: 8076546

Group type: EXPERIMENTAL
Intervention: Intranasal oxygen supplementation
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Intrapharyngeal oxygen supplementation
Number of subjects: 79

Group type: COMPARATOR
Intervention: No supplementary oxygen (lower-risk group)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Supplementary oxygen (lower-risk group)
Number of subjects: 79
Study: 3396490

Group type: EXPERIMENTAL
Intervention: Cefotaxime 2g intravenously
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2g intravenously
Number of subjects: 27

Group type: COMPARATOR
Intervention: No antibiotic (controls)
Number of subjects: 27
Study: 31538282

Group type: EXPERIMENTAL
Intervention: Sildenafil (REVATIO®)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical trial simulations
Number of subjects: 0
Study: 28741805

Group type: EXPERIMENTAL
Intervention: Auricular noninvasive magnetic acupuncture (MA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 40